Opportunities for personalized approaches in heart failure

Abstract

The diagnosis of heart failure (HF) remains difficult, as do the prediction of the prognosis of HF patients and personalizing the selection of drugs and devices used to treat specific individuals. Other than natriuretic peptides, which are useful diagnostic and prognostic biomarkers, few tools are available to personalize the management of HF patients. Investigations of rare, monogenic forms of HF have improved our understanding of HF and the management of these patients and their families. Yet, few genes have been associated with the common, polygenic forms of HF. The discovery of tools useful to predict the patients most likely to benefit from a specific drug remains a critically unmet need.